Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226863 | 0.89 | HRH3 (0.47) | HRH3KDM4EALDH1A1UTS2RHTT | |
| SCHEMBL4233533 | 0.82 | HRH3 (0.54) | HRH3KDM4EUTS2ROPRM1OPRK1 | |
| SCHEMBL4233913 | 0.80 | KCNH2 (0.58) | KDM4EALDH1A1UTS2ROPRM1OPRK1 | |
| SCHEMBL10088647 | 0.79 | PDE4B (0.52) | HRH3KDM4EALDH1A1HTTOPRM1 | |
| SCHEMBL4242600 | 0.79 | HRH3 (0.49) | HRH3MEN1KMT2A | |
| SCHEMBL4237296 | 0.79 | PDE4A (0.56) | SLC5A7 | |
| SCHEMBL28047777 | 0.76 | PDE4B (0.60) | HRH3OPRM1OPRK1KCNH2KMT2A | |
| SCHEMBL4232317 | 0.76 | SSTR5 (0.46) | HRH3UTS2RPOLBHTTOPRM1 | |
| SCHEMBL4237246 | 0.76 | EPHX2 (0.51) | ALDH1A1UTS2RKCNH2MEN1KMT2A | |
| SCHEMBL27865407 | 0.74 | KDM4E (0.58) | HRH3KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885KDM4E 1604/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.